Revolutionizing Precision Oncology Through Cutting-Edge Epigenomic Biomarkers & AI-Enabled Data Solutions

• Integrate genomic and epigenomic insights to enhance understanding of tumor behavior
• Leverage ctDNA and epigenomic biomarkers for response prediction, cancer subtyping, and detection of treatment-emergent resistance
• Explore how Guardant Infinity and InfinityAI unite innovative testing with multimodal data solutions to deliver novel epigenomics biomarkers from research to clinic

Speakers:

Brad Sickler

Director, Translational Medicine Bioinformatics

Revolution Medicines

Sumit Kar

Director

Revolution Medicines

Jean-Francois Martini

Sr Director, Translational strategy

Guardant Health